Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of EuTCV in Healthy Adults
NCT03956524Phase 1Completed
- Sponsor
- EuBiologics
- Start
- Mar 2019
- Primary completion
- Aug 2019
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of EuTYPH-C in typhoid fever (3 arms), sponsored by EuBiologics. Primary endpoints: Local and systemic solicited adverse events at Day 7, Unsolicited adverse events at 6 weeks and 1 more. Started Mar 2019; status: completed.
02
Drugs
EuTYPH-C
03
Conditions
typhoid fever
Beyond the preview
Go deeper on NCT03956524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03956524.